Thoralf Lange, Thomas Ernst, Franz X. Gruber, Jacqueline Maier, Michael Cross, Martin C. Müller, Dietger Niederwieser, Andreas Hochhaus, Markus Pfirrmann. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica 2013;98(5):714-717; https://doi.org/10.3324/haematol.2012.068890.